1. Frazzi, Raffaele. 2021. BIRC3 and BIRC5: multi-faceted inhibitors in cancer. In Cell & bioscience, 11, 8. doi:10.1186/s13578-020-00521-0. https://pubmed.ncbi.nlm.nih.gov/33413657/
2. Nadeu, Ferran, Delgado, Julio, Royo, Cristina, Enjuanes, Anna, Campo, Elías. 2016. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. In Blood, 127, 2122-30. doi:10.1182/blood-2015-07-659144. https://pubmed.ncbi.nlm.nih.gov/26837699/
3. Wang, Sixu, Zhao, Meishan, Zhang, Xiaofei, Tian, Ye, Qiu, Wei. 2023. Birc3 and Tip1 are upregulated in renal ischemia reperfusion injury. In Gene, 876, 147492. doi:10.1016/j.gene.2023.147492. https://pubmed.ncbi.nlm.nih.gov/37209886/
4. Meng, Qingliang, Wei, Kai, Shan, Yu. 2024. E3 ubiquitin ligase gene BIRC3 modulates TNF-induced cell death pathways and promotes aberrant proliferation in rheumatoid arthritis fibroblast-like synoviocytes. In Frontiers in immunology, 15, 1433898. doi:10.3389/fimmu.2024.1433898. https://pubmed.ncbi.nlm.nih.gov/39301019/
5. Du, Lijuan, Xu, Changyi, Zeng, Zhimin, Liang, Yuxia, Guo, Yubiao. 2022. Exploration of induced sputum BIRC3 levels and clinical implications in asthma. In BMC pulmonary medicine, 22, 86. doi:10.1186/s12890-022-01887-2. https://pubmed.ncbi.nlm.nih.gov/35287655/